Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Trevena, Inc.
  6. Summary
    TRVN   US89532E1091

TREVENA, INC.

(TRVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/19/2021 07/20/2021 07/21/2021 07/22/2021 07/23/2021 Date
1.48(c) 1.54(c) 1.6(c) 1.56(c) 1.47(c) Last
1 288 134 1 465 317 952 743 728 342 1 986 273 Volume
-1.99% +4.05% +3.90% -2.50% -5.77% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 8,82 M - -
Net income 2021 -45,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,11x
Yield 2021 -
Sales 2022 26,2 M - -
Net income 2022 -39,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,94x
Yield 2022 -
Capitalization 242 M 242 M -
Capi. / Sales 2021 27,4x
Capi. / Sales 2022 9,21x
Nbr of Employees -
Free-Float 98,9%
More Financials
Company
Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory... 
More about the company
Ratings of Trevena, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about TREVENA, INC.
07/23Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shar..
GL
07/12TREVENA : Announces Publication of OLINVYK« Health Economic Model in Journal of ..
AQ
07/12Trevena Announces Publication of OLINVYK« Health Economic Model in Journal of..
CI
07/08TREVENA : Enrolls First Patient in Late-Stage Study of Olinvyk Injection in Chin..
MT
07/08Trevena Announces First Patient Enrolled in OLINVYK« Phase 3 Trial in China i..
GL
07/07TREVENA : Launches Study to Assess Physiologic Impact of Olinvyk on Respiratory ..
MT
07/07Trevena Announces Initiation of OLINVYK« Respiratory Physiology Study Includi..
GL
07/07Trevena, Inc. Announces Initiation of Olinvyk« Respiratory Physiology Study I..
CI
06/28INSIDER TRENDS : 90-Day Insider Selling Trend Reduced with Purchase of Shares of..
MT
06/28Trevena Added to Russell 2000«, Russell 3000«, and Russell Microcap« Indexes
GL
06/16TREVENA INC : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
06/16TREVENA : Thinking about buying stock in Catabasis Pharmaceuticals, Arrival, Man..
PR
06/16TREVENA : Patient Recruiting Resumes for Study of Trevena's TRV734 to Treat Opio..
MT
06/16Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Stu..
GL
06/16Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Stu..
CI
More news
News in other languages on TREVENA, INC.

- No features available -

More news
Analyst Recommendations on TREVENA, INC.
More recommendations
Chart TREVENA, INC.
Duration : Period :
Trevena, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TREVENA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 1,47 $
Average target price 5,33 $
Spread / Average Target 263%
EPS Revisions
Managers and Directors
Carrie L. Bourdow President, Chief Executive Officer & Director
Barry Shin Chief Financial Officer & Senior Vice President
Leon O. Moulder Chairman
Mark A. Demitrack Chief Medical Officer & Senior Vice President
Michael J. Fossler VP-Clinical Development & Quantitative Sciences
Sector and Competitors
1st jan.Capi. (M$)
TREVENA, INC.-31.31%321
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308